{
    "nct_id": "NCT06331468",
    "official_title": "Phase II Trial of Hypofractionated Radiochemotherapy for Women With Metastatic or Bulky Uterine Cervix Cancer",
    "inclusion_criteria": "* Untreated, pathologically or cytologically-confirmed diagnosis of FIGO Stage IB3, II, or IIIA-IIIC1 bulky ( â‰¥ 6cm) or Stage IVB (FIGO 2018) squamous, adenosquamous, or adenocarcinoma of the uterine cervix with limited metastatic burden (not requiring urgent systemic therapy).\n* Adequate organ and marrow function\n* Gynecologic Oncology Group performance status of 0, 1, or 2\n* Patient agrees to use two forms of birth control if they are of child-bearing potential\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
    "exclusion_criteria": "* Presence of another concurrent active invasive malignancy\n* Prior invasive malignancy diagnosed within the last three years, with the following two exceptions: [a] non-melanoma skin cancer and/or [b] prior in situ carcinoma of the cervix\n* Receipt of prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues, at the discretion of the treating physician\n* Currently receiving any other investigational agent(s) for the treatment of cancer\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cisplatin or other agents used in study\n* Presence of uncontrolled intercurrent illness as determined by the treating physician\n* pregnant or lactating\n* Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better",
    "miscellaneous_criteria": ""
}